Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Snapshot | 7 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Overview | 7 | 1 |
| Key Information | 7 | 1 |
| Key Facts | 7 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Research and Development Overview | 8 | 3 |
| Key Therapeutic Areas | 8 | 3 |
| Daewoong Pharmaceutical Co., Ltd. Pipeline Review | 11 | 3 |
| Pipeline Products by Stage of Development | 11 | 1 |
| Pipeline Products Monotherapy | 12 | 1 |
| Pipeline Products Combination Treatment Modalities | 13 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Pipeline Products Glance | 14 | 6 |
| Daewoong Pharmaceutical Co., Ltd. Late Stage Pipeline Products | 14 | 1 |
| Pre-Registration Products/Combination Treatment Modalities | 14 | 1 |
| Phase III Products/Combination Treatment Modalities | 15 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products | 16 | 1 |
| Phase II Products/Combination Treatment Modalities | 16 | 1 |
| Phase I Products/Combination Treatment Modalities | 17 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Early Stage Pipeline Products | 18 | 1 |
| Preclinical Products/Combination Treatment Modalities | 18 | 1 |
| Discovery Products/Combination Treatment Modalities | 19 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Drug Profiles | 20 | 27 |
| DWJ-1261 | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 1 |
| nepidermin | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 1 |
| onabotulinumtoxin A | 22 | 1 |
| Product Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D Progress | 22 | 1 |
| (olmesartan medoxomil + rosuvastatin calcium) | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| DWP-05195 | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| DWC-20151 | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| DWC-20152 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| DWP-09031 | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| DWP-10292 | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| DWP-14012 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| DWJ-1303 | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 1 |
| DWJ-1308 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| DWJ-1325 | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| DWJ-1340 | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| DWJ-1351 | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| DWJ-1355 | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| DWJ-1365 | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| DWJ-1366 | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| DWJ-206 | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| DWJ-208 | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| DWJ-209 | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| DWP-06081 | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| Protein for Undisclosed Indication | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| DWJ-1367 | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 1 |
| DWJ-205 | 44 | 1 |
| Product Description | 44 | 1 |
| Mechanism of Action | 44 | 1 |
| R&D Progress | 44 | 1 |
| DWJ-210 | 45 | 1 |
| Product Description | 45 | 1 |
| Mechanism of Action | 45 | 1 |
| R&D Progress | 45 | 1 |
| DWP-457 | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Pipeline Analysis | 47 | 4 |
| Daewoong Pharmaceutical Co., Ltd. Pipeline Products by Target | 47 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Pipeline Products by Route of Administration | 48 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Pipeline Products by Molecule Type | 49 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Pipeline Products by Mechanism of Action | 50 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Recent Pipeline Updates | 51 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Dormant Projects | 52 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Discontinued Pipeline Products | 53 | 1 |
| Discontinued Pipeline Product Profiles | 53 | 1 |
| lagociclovir | 53 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Company Statement | 54 | 1 |
| Daewoong Pharmaceutical Co., Ltd. Locations And Subsidiaries | 55 | 2 |
| Head Office | 55 | 1 |
| Other Locations &Subsidiaries | 55 | 2 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |